Completed PHASE2 INTERVENTIONAL 1-arm NCT00525148

LUX Lung 2 Phase II Single Arm BIBW 2992 Afatinib in NSCLC With EGFR Activating Mutations

LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations

Sponsor: Boehringer Ingelheim

Conditions Carcinoma, Non-Small-Cell Lung

Interventions BIBW 2992

Updated 7 times since 2017 Last updated: Jul 28, 2016 Started: Aug 31, 2007 Primary completion: Feb 28, 2010 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Carcinoma, Non-Small-Cell Lung, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 7 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Dec 2025 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Bakersfield, United States , Bethesda, United States , Beverly Hills, United States , Boston, United States , Canton, United States , Chicago, United States , Fairfax, United States , Flint, United States , Fort Lauderdale, United States and 16 more locations